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to vary by the academic centre appraising the submission, reflecting the 
inherent objectivity and uniform implementation of NICE methodology.  
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OBJECTIVES: Chronic disease is resource intensive for health care systems. 
Considerable efforts have focused on the management of chronic disease in the 
community setting however the role of individual health technologies is often 
overlooked. The purpose of this analysis was to identify examples of individual 
health technologies that contribute to overall chronic disease management. 
METHODS: The Medical Advisory Secretariat (MAS) in Ontario has published a 
substantive body of evidence-based analyses on health technologies. The MAS 
Ontario Health Technology Assessment Series was searched for reports 
published between 2006 and 2011. Findings were limited to analyses that 
reported on health technologies with moderate to high quality evidence of 
effectiveness for chronic disease management. Outcomes of interest included 
health resource utilization, patient and clinical outcomes, and economic 
analyses measures. RESULTS: Two technologies had direct evidence of the cure 
of chronic disease. Bariatric surgery was effective in the resolution of diabetes 
among morbidly obese adults (77% resolution; 95% CI 71%-83%), with a cost of 
$15,697 Canadian dollars (CAD) per quality-adjusted life year (QALY) relative to 
usual care. Ablation for atrial fibrillation resulted in greater freedom from 
arrhythmia than medical treatment alone (RR 0.30; 95% CI 0.11-0.79), and 
downstream cost savings. Two technologies were effective in the prevention of 
chronic wounds and 8 technologies were effective in the management of chronic 
obstructive pulmonary disease, stroke, coronary artery disease, congestive heart 
failure or benign prostatic hyperplasia. Among these 10 technologies, all 5 
analyses that reported incremental cost-effectiveness ratios were cost-effective 
based on a $50,000 (CAD) per QALY threshold. CONCLUSIONS: This review 
demonstrates that individual health technologies can be both effective and  
cost-effective in the overall management of chronic disease. Therefore  
health technologies can be a viable contributing factor to chronic disease 
management and should be considered as an integral component of community 
health care.  
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OBJECTIVES: To compare the German (AMNOG) and French (ASMR) category 
scoring pricing systems; and to evaluate whether the two agencies have a similar 
interpretation of innovation and clinical benefit of the same drugs. Our results 
then allow us to theorize the future of European scoring systems. METHODS: A 
search of the G-BA website was conducted to identify all drug-related Health 
Technology Assessments (HTA) published between January 2011 and December 
2012. Once a list of assessments was compiled, we searched the HAS website to 
identify the same drug HTAs published within the same time period. Then, for 
both agencies we identified and compared the methods in which they scored 
both innovation and clinical benefits of these drugs. To note: Germany (G-BA) 
provide AMNOG scorings from 1 (substantial benefit) to 6 (negative additional 
benefit), whilst France (HAS) provide ASMR scorings from I (major improvement) 
to V (no improvement). RESULTS: In this time period, sixteen HTAs were 
published by the G-BA, corresponding to 12 HTAs published by HAS. Upon 
observation of the scoring comparisons, only 3 of the 12 drugs were given the 
same scores by both agencies: Fampridine (AMNOG 5; ASMR V); Cabazitaxel 
(AMNOG 3; ASMR III); Linagliptin (AMNOG 5; ASMR V). For the remaining 12 
drugs, there appeared to be little alignment in the scorings of innovation and 
clinical benefits: Vemurafenib (AMNOG 2; ASMR III), Vandetanib (5; IV), 
Belatacept (3; V), Apixaban (3; IV), Eribulin (6; IV), Collagenase clostridium 
histolyticum (5; no score), Abiraterone acetate (5; III), Fingolimod (3; IV) and 
Ticagrelor (2 and 5; IV). CONCLUSIONS: There does not seem to be a strong 
relationship between the criteria scoring of AMNOG and ASMR, demonstrating 
the heterogeneity of the European market. Whether increased HTA co-operation 
will align scoring more closely, or increased Value Based Pricing structures will 
drive divergence, is yet to be seen.  
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OBJECTIVES: The main aim of this study was to identify significant implicit and 
explicit factors which play a role in decision making of the Scottish Medicines 
Consortium (SMC). Once these factors have been identified, the degree to which 
they influence the final decision will be ascertained. METHODS: A retrospective 
sample of submissions was taken from the SMC website. A bivariate statistical 
analysis was performed on the data extracted, allowing identification of the 
most fundamental drivers of an SMC decision. RESULTS: Between January 2006 
and September 2011, 577 appraisals were made by the SMC. Of these appraisals, 
27% accepted for full use, 30% were accepted for restricted use, whilst 43% of 
submissions were not recommended for use in Scotland. During this time period, 
the mean ICER for drugs accepted for use is £30,013 and for those that were not 
recommended for use the value was £38,132. Analysis of over 500 submissions to 
the SMC showed that a number of explicit, key drivers in line with SMC criteria 
were significant, including; the unofficial £30,000 ICER limit, the use of 
appropriate economic and clinical comparators, as well as robust demonstration 
of the economic case. Other key drivers which are more implicit, yet critical to 
decision making, were also shown to be significant. These included; the orphan 
status, submissions targeting paediatric populations and restrictions on the 
therapeutic scope of submissions placed by manufacturers. CONCLUSIONS: 
From a manufacturer point of view understanding the tendencies of the SMC is 
critical, as a firmer understanding of the key determinants of the SMC decision 
may lead to improved quality and robustness of future submissions. From the 
perspective of the SMC and the wider society, these insights will allow the public 
and the SMC to review the drivers of the decisions to establish whether they are 
in line with official criteria.  
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OBJECTIVES: Many non-drug technologies with regulatory approval fail to be 
recommended for reimbursement. Reasons include low quality evidence or lack 
of relevance Excellence in Clinical Innovation and Technology Evaluation 
(EXCITE) is a collaboration between industry, government and academia to 
develop a harmonized pre-market evaluation that mitigates risk, improves 
adoption, and responds to system needs METHODS: EXCITE works with industry 
to evaluate evidence of efficacy and safety, cost effectiveness and adoption 
realities. It builds on Ontario’s field evaluation experience. Structure: 1) 
Management board representing industry, government, academia and the 
Ontario Health Technology Advisory Committee (OHTAC); 2) Scientific 
collaboration of 7 Methodological Centres (MC) and 24 Academic Health Science 
Centres and a Quality Assurance Committee; and 3) Chief Scientific Officer and 
secretariat. Process: The management board prioritizes applications based on 
innovation, relevance, and commercialization. MCs develop a protocol and 
budget for clinical evaluation, systematic review, and an economic analysis. 
Human factors and usability analysis, and preference studies are offered. 
Consideration is underway for conditions of early adoption. Studies are funded 
by industry through MaRS, which fosters and commercializes innovation. 
RESULTS: Of 17 applications (year 1), 3 have commenced evaluation, 3 are in 
protocol development, discussions ongoing in 3 and one declined. Studies are 
designed to satisfy regulatory and reimbursement requirements and reflect 
complexities of adoption while maintaining high academic standards. Lessons 
learnt include a better understanding of the complexities of adoption and the 
benefit of endorsement in mitigating risk; limited funding for evaluations; 
tension between needs of industry and independence and objectivity of MCs; 
and intricacies of contract structures. CONCLUSIONS: EXCITE is a potential 
alternative to post-market HTA in Ontario, and may improve adoption in other 
jurisdictions. Expansion to a national and international scale will provide global 
reach for evaluated technologies. This is a potentially innovative and powerful 
model of early HTA.  
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OBJECTIVES: Cost effectiveness analyses play a critical role in determining 
coverage of novel drugs and devices. Increasingly, payers are demanding 
subgroup analyses to determine indications which would be covered by  
the national health system or insurance agency. METHODS: To understand  
and review trends in the use of subgroup cost effectiveness analysis, we 
analyzed NICE HTAs for products approved between 2011-2012. Manufacturer 
submissions for CEA were compared to final review and decision by HTA agency. 
Analogs were identified and case studies were developed to further understand 
the use of subgroup analyses and cost effectiveness models. RESULTS: Decisions 
made by NICE in 2011-2012 show increasing trends towards the use of subgroup 
analysis for determining indications for coverage by national payer bodies. 
Between 2011-2012, 80% of the assessments included subgroup analyses. 
Approximately half of them included cost effectiveness analyses for various 
subgroups. Interestingly, the ICER values estimated by NICE for the same 
subgroups showed a large variation (1X-3X fold difference) compared to ICER 
values estimated by manufacturers. Selected case studies highlighted that for 
several products, NICE is recommending treatments only for subgroups whose 
ICER values are within the cost effectiveness threshold. CONCLUSIONS: New 
products need robust broader population and subgroup analyses for insurance 
coverage.  
